肝硬化性脑病：预防与管理
Encephalopathy in Cirrhosis: Prevention and Management.
作者信息
Sahney Amrish, Wadhawan Manav
机构信息
Institute of Digestive & Liver Diseases, BLK Superspeciality Hospital, Delhi, India.
出版信息
J Clin Exp Hepatol. 2022 May-Jun;12(3):927-936. doi: 10.1016/j.jceh.2021.12.007. Epub 2021 Dec 22.
Abstract
Hepatic encephalopathy (HE) is a major neuropsychiatric complication of cirrhosis. The clinical manifestations of HE ranges from mild confusion, disorientation to altered behaviour and coma in advanced stages. HE is an important cause of recurrent admissions in liver cirrhosis patients. HE is the most common cause of altered mentation in a patient of liver cirrhosis. Lactulose and rifaximin are approved treatment options for the treatment of HE. In patients who have localised neurological signs or are not improving with lactulose and rifaximin should be investigated for other causes of altered sensorium.
摘要
肝性脑病（HE）是肝硬化的一种主要神经精神并发症。HE的临床表现从轻度意识模糊、定向障碍到晚期行为改变和昏迷不等。HE是肝硬化患者反复住院的重要原因。HE是肝硬化患者意识改变最常见的原因。乳果糖和利福昔明是已获批用于治疗HE的药物。对于有局部神经体征或使用乳果糖和利福昔明治疗效果不佳的患者，应排查导致感觉改变的其他原因。
相似文献
1
Encephalopathy in Cirrhosis: Prevention and Management.
J Clin Exp Hepatol. 2022 May-Jun;12(3):927-936. doi: 10.1016/j.jceh.2021.12.007. Epub 2021 Dec 22.
2
Management of hepatic encephalopathy in the hospital.
Mayo Clin Proc. 2014 Feb;89(2):241-53. doi: 10.1016/j.mayocp.2013.11.009. Epub 2014 Jan 8.
3
Combined Balloon-, Plug- and Coil-assisted Retrograde Transvenous Obliteration of Multiple Portosystemic Shunts to Treat Recurrent Hepatic Encephalopathy: A Case Report.
J Clin Exp Hepatol. 2020 Jul-Aug;10(4):402-406. doi: 10.1016/j.jceh.2019.12.002. Epub 2019 Dec 26.
4
Retrograde Transvenous Obliteration (RTO): A New Treatment Option for Hepatic Encephalopathy.
Dig Dis Sci. 2020 Sep;65(9):2483-2491. doi: 10.1007/s10620-020-06050-7. Epub 2020 Jan 31.
5
Results of Portosystemic Shunt Embolization in Selected Patients with Cirrhosis and Recurrent Hepatic Encephalopathy.
J Clin Exp Hepatol. 2017 Dec;7(4):300-304. doi: 10.1016/j.jceh.2017.03.012. Epub 2017 Apr 14.
6
Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
Am J Med. 2021 Nov;134(11):1330-1338. doi: 10.1016/j.amjmed.2021.06.007. Epub 2021 Jul 7.
7
Modified Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) Techniques for the Treatment of Gastric Varices: Vascular Plug-Assisted Retrograde Transvenous Obliteration (PARTO)/Coil-Assisted Retrograde Transvenous Obliteration (CARTO)/Balloon-Occluded Antegrade Transvenous Obliteration (BATO).
Cardiovasc Intervent Radiol. 2018 Jun;41(6):835-847. doi: 10.1007/s00270-018-1896-1. Epub 2018 Feb 7.
8
Efficacy and Safety of Variable Treatment Options in the Prevention of Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.
Cureus. 2024 Jan 31;16(1):e53341. doi: 10.7759/cureus.53341. eCollection 2024 Jan.
9
Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
Am J Med Sci. 2018 Sep;356(3):296-303. doi: 10.1016/j.amjms.2018.06.008. Epub 2018 Jun 19.
10
Pharmacotherapy for hepatic encephalopathy.
Drugs. 2010 Jun 18;70(9):1131-48. doi: 10.2165/10898630-000000000-00000.
引用本文的文献
1
Incidental Findings in Clinical Practice: A Case of Hepatic Encephalopathy and Subsequent Lung Cancer Detection.
Cureus. 2025 Jul 18;17(7):e88245. doi: 10.7759/cureus.88245. eCollection 2025 Jul.
2
The Role of Vitamin D Deficiency in Hepatic Encephalopathy: A Review of Pathophysiology, Clinical Outcomes, and Therapeutic Potential.
Nutrients. 2024 Nov 23;16(23):4007. doi: 10.3390/nu16234007.
3
Management of Portal Hypertension.
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1184-1199. doi: 10.1016/j.jceh.2022.03.002. Epub 2022 Mar 21.
本文引用的文献
1
Cognitive Impairment After Resolution of Hepatic Encephalopathy: A Systematic Review and Meta-Analysis.
Front Neurosci. 2021 Mar 10;15:579263. doi: 10.3389/fnins.2021.579263. eCollection 2021.
2
Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2626-2635.e7. doi: 10.1016/j.cgh.2020.10.019. Epub 2020 Oct 16.
3
Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis.
Nutr J. 2019 Jul 6;18(1):34. doi: 10.1186/s12937-019-0461-3.
4
Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
Drugs. 2019 Feb;79(Suppl 1):23-29. doi: 10.1007/s40265-018-1023-2.
5
EASL Clinical Practice Guidelines on nutrition in chronic liver disease.
J Hepatol. 2019 Jan;70(1):172-193. doi: 10.1016/j.jhep.2018.06.024. Epub 2018 Aug 23.
6
Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
Can J Gastroenterol Hepatol. 2018 Jul 10;2018:3015891. doi: 10.1155/2018/3015891. eCollection 2018.
7
Exercise in cirrhosis: Translating evidence and experience to practice.
J Hepatol. 2018 Nov;69(5):1164-1177. doi: 10.1016/j.jhep.2018.06.017. Epub 2018 Jun 30.
8
Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.
Pharmacoeconomics. 2018 Jul;36(7):809-822. doi: 10.1007/s40273-018-0641-6.
9
Why and when to measure ammonemia in cirrhosis?
Clin Res Hepatol Gastroenterol. 2018 Dec;42(6):505-511. doi: 10.1016/j.clinre.2018.01.004. Epub 2018 Mar 16.
10
L-ornithine L-aspartate in bouts of overt hepatic encephalopathy.
Hepatology. 2018 Feb;67(2):700-710. doi: 10.1002/hep.29410. Epub 2017 Dec 27.
Zotero 插件